Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
ATMH All Things Mobile Analytic Inc
INCT Incapta Inc
BML-J Bank of America Corp
PEP PepsiCo Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Closing Price
$245.49
Day's Change
3.83 (1.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
246.84
Day's Low
240.02
Volume
(Above Average)
Volume:
2,855,245

10-day average volume:
2,453,613
2,855,245

Intuit, Credit Karma reach deal with DOJ to help complete $7.1 billion merger

10:00 am ET November 25, 2020 (MarketWatch)
Print

Shares of Intuit Inc. (INTU) rose 1.7% in morning trading, after the parent of TurboTax tax preparation software said it reached an agreement with the Department of Justice (DOJ) regarding its proposed $7.1 billion acquisition of Credit Karma (http://www.marketwatch.com/story/intuit-makes-it-official-plans-to-buy-credit-karma-for-71-billion-2020-02-24), in which the Credit Karma Tax business will be sold to Square Inc. (SQ) to help assuage antitrust concerns. The deal with Square (http://www.marketwatch.com/story/square-stock-falls-after-report-says-company-in-talks-to-acquire-tax-prep-business-from-credit-karma-2020-10-30) is contingent on the closing of the Intuit-Credit Karma merger. As part of the deal with Square, Intuit and Credit Karma will committed to provide certain transition services. Square's stock rallied 3.0% in morning trading. "We are pleased to have cleared this necessary regulatory review with DOJ and appreciate their careful consideration of this transaction," said Intuit Chief Executive Sasan Goodarzi. "Consumers will continue to benefit from the Credit Karma Tax product as part of Square." Intuit shares have rallied 33.9% year to date, while Square's stock has rocketed 234.0% and the S&P 500 has gained 12.2%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 25, 2020 10:00 ET (15:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.